Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications

被引：15

作者：

Kaur K. ^{[1
]}

Gandhi M.A. ^{[1
]}

Slish J. ^{[1
]}

机构：

[1] St John Fisher College Wegmans School of Pharmacy, Rochester, NY

来源：

Infectious Diseases and Therapy | 2015年 / 4卷 / 2期

关键词：

HCV; HIV; HIV–HCV drug interactions;

D O I：

10.1007/s40121-015-0061-2

中图分类号：

学科分类号：

摘要：

One-fourth of individuals diagnosed with the human immunodeficiency virus concomitantly have the hepatitis C virus infection. Since the discovery of highly active antiretroviral therapy, liver complications have become the leading cause of morbidity and mortality in HIV-HCV coinfected individuals. Optimal treatment in this patient population is critical, as coinfection has been linked to deterioration of both disease states. The objective of this review article is to highlight the current literature on drug-drug interactions between HIV and HCV treatments. The management of the treatment of coinfection patients has been covered extensively in numerous other publications. © 2015, The Author(s).

引用

页码：159 / 172

页数：13

共 37 条

[1]

Puotia M., Rossottia R., Travia G., Et al., Optimizing treatment in HIV/HCV co-infection, Dig Liver Dis, 45S, pp. 355-362, (2013)

[2]

Deeks E.D., Perry C.M., Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla RM): a review of its use in the management of HIV infection, Drugs., 70, 17, pp. 2315-2338, (2010)

[3]

Soriano V., Vispo E., Labarga P., Et al., Viral hepatitis and HIV co-infection, Antivir Res, 85, 1, pp. 303-315, (2010)

[4]

Weber R., Sabin C.A., Friis-Miller N., Et al., Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A: D study, Arch Intern Med, 166, 15, pp. 1632-1641, (2006)

[5]

Limketkai B.N., Mehta S.H., Sutcliffe C.G., Et al., Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults co-infected with HIV/HCV, JAMA, 308, 4, pp. 370-378, (2012)

[6]

Gilead Sciences, (2014)

[7]

Lawitz E., Mangia A., Wyles D., Et al., Sofosbuvir for previously untreated chronic hepatitis C infection, N Engl J Med, 368, pp. 1878-1887, (2013)

[8]

Kowdley K.V., Lawitz E., Crespo I., Et al., Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomized, multicentre phase 2 trial, Lancet, 381, pp. 2100-2107, (2013)

[9]

Jacobson I.M., Gordon S.C., Kowdley K.V., Et al., Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options, N Engl J Med, 368, pp. 1867-1877, (2013)

[10]

Boehringer Ingelheim Pharmaceuticals, (2014)

← 1 2 3 4 →